Navigation Links
PeaceHealth Laboratories' New Patent Addresses a Leading Cause of Death: Prescription Drug Abuse
Date:5/30/2012

SPRINGFIELD, Ore., May 30, 2012 /PRNewswire/ -- PeaceHealth Laboratories today announced the national availability and receipt of a federal patent for PtProtect™ (Patient Protect), a pain medication monitoring program offering the industry's highest levels of accuracy to detect prescription pain medication and identify potential negative drug interactions before they occur. PtProtect directly addresses the safety and financial concerns of prescription pain medication abuse by using the most sensitive and definitive assays to detect medication and illicit drugs.

In the most recent review period January – April, 2012, PeaceHealth Laboratories found that 35 percent of PtProtect test results returned discrepant results outside a patient's known prescriptions. Because PtProtect identifies patients who are taking or potentially diverting prescribed pain medications, taking pain medications that are not prescribed to them, or using drugs of abuse it has the potential to significantly reduce accidental deaths. (1)

"PtProtect saves lives, saves practices and saves communities money," said Ran Whitehead, Chief Executive Officer of PeaceHealth Laboratories. "Now physicians may know, with confidence, what pain medications their patient is taking and prescribe accordingly to the highest levels of safety. This patent validates our rigorous science and practical application of this life-saving technology. It also enables providers to protect their practices from uncertain liabilities including malpractice and patient mortality."

In recognition of PtProtect's technology and capabilities, the U.S. Patent and Trademark Office issued U.S. Patent No. 8,067,243 granting exclusive rights to PtProtect™.  

About PtProtect

PtProtect is a patented testing program that detects up to 38 prescribed medications and illicit drugs. Medications are revealed at the industry's lowest thresholds for the most sensitive, comprehensive detection of opiates and opioids, thus reducing the possibility of adverse drug interactions. Simple and timely reporting allows doctors to quickly determine if test results are consistent or inconsistent with patient prescriptions.

PtProtect is available through PeaceHealth Laboratories and may be administered by physicians nationwide. For information about PtProtect, visit www.ptprotect.com or call 800-826-3616.

About PeaceHealth Laboratories

PeaceHealth Laboratories is a division of PeaceHealth, a not-for-profit health care system with a mission of promoting personal and community health since 1890. PeaceHealth Laboratories provides comprehensive laboratory services throughout the Pacific Northwest (Oregon, Washington and Alaska), and specialty testing for clinicians and employers across the U.S. With 9 laboratories and 27 patient service centers in three states, PeaceHealth Laboratories is one of the largest laboratory systems in the Pacific Northwest. Learn more at www.peacehealthlabs.org

(1) Source: CNNMoney February 24, 2012


'/>"/>
SOURCE PeaceHealth Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PeaceHealth Standardizes Hematology Operations With Sysmex
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
4. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
5. Romark Laboratories Raises $18 Million in Institutional Financing
6. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
7. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
8. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
9. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
10. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
11. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)...  As the latest Obamacare repeal effort moves is ... (R-LA) and Lindsey Graham (R-SC) medical device ... industry is in an odd place.  The industry wants ... tax on medical device sales passed along with the ... increased visits and hospital customers with the funding to ...
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
(Date:9/13/2017)... 13, 2017   OrthoAtlanta has been named the ... Host Committee (AFHC) for the 2018 College Football Playoff (CFP) ... at Mercedes-Benz Stadium in Atlanta, Georgia . ... "I,m In" campaign, participating in many activities leading up to, ... ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... , ... "Success Files," a short- and long-form documentary style ... disease estimated to affect the lives of more than 5 million Americans living ... leading voice in the fight for cure and research into the disease, its ...
(Date:9/22/2017)... ... , ... “Letters From Home”: a moving compilation of letters that remind ... “Letters From Home” is the creation of published author, John Allred, a passionate leader ... Savelle Ministries International, who has traveled and ministered on four continents. , “It is ...
(Date:9/22/2017)... Greenwich, Connecticut (PRWEB) , ... September 22, 2017 ... ... to conquering Lyme and other tick-borne diseases through research, education and awareness, today ... , A noted immunologist and microbiologist, Dr. Sellati has more than 20 ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process Capability ... p.m. – 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      , Quality ... run afoul of The Quality System Regulation (§820.250), and Devicemakers find themselves staring ...
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional Communication:, Keeping Up with ... In the competitive world of drug and device marketing and promotion, drug and ... rules. , The FDA has issued two draft guidances that are the closest ...
Breaking Medicine News(10 mins):